In another study, blood samples were collected every two months until disease progression from NSCLC patients with epidermal growth factor receptor(EGFR) mutations who were receiving erlotinib treatment; analysis revealed that in lung cancer patients,CTC assessmentbased on blood samples can complement EGFR mutationassessmentbased on tissue samples. The gene discussed is EGFR; the disease is lung carcinoma.